NCT07657338Not yet recruiting
Effect of Chinese Herbal Medicine on Kidney Function in Non-Diabetic CKD
Effects of Chinese Herbal Medicine as an Adjunctive Therapy on Renal Function in Patients With Non-Diabetic Chronic Kidney Disease: A Pilot Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 18 Jun 2026
Brief summary (registry, in English)
This study is a randomized controlled pilot trial designed to evaluate the effects and safety of a traditional Chinese medicine formula (CKD-1) as an add-on therapy to standard treatment in patients with stage 3-4 non-diabetic chronic kidney disease. Eligible participants will be randomly assigned to receive either standard care alone or standard care combined with CKD-1 for 12 weeks. Kidney function, urine protein levels, and quality of life will be assessed before and after the intervention. The study aims to provide preliminary evidence on whether CKD-1 can improve renal function and quality of life in this patient population.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 66 (estimated)
- First submitted
- 15 Jun 2026
- Start date
- 11 Jun 2026
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- China Medical University Hospital
- Diseases
- Chronic kidney disease
- NCT number
- NCT07657338
What you commit to
- Study type: Interventional
- Planned participants: 66
- From 11 Jun 2026 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Acute kidney injury or major kidney-related surgery within 3 months prior to enrollment.
- Malignancy currently receiving chemotherapy, radiotherapy, or other systemic anticancer treatment.
Other illness
- History of diabetes mellitus.
- End-stage disease defined under palliative care regulations.
- Known allergy to any components of the CKD-1 herbal formula, including Astragalus membranaceus, Salvia miltiorrhiza, Poria cocos, Moutan cortex, Scutellaria baicalensis, Lonicera japonica, or Alisma orientale.
Lab values
- Alanine aminotransferase (ALT) levels greater than 3 times the upper limit of normal.
Other
- Participation in another clinical trial within 3 months that may affect renal function.
- Pregnancy or breastfeeding.
Who the study is looking for
- Adults aged ≥18 years.
- Patients diagnosed with stage 3-4 chronic kidney disease (CKD), confirmed by a nephrologist and classified as ICD-10-CM codes N18.3-N18.4.
- Ability to understand the study procedures and provide written informed consent.
- Willingness to comply with study procedures and follow-up visits.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| China Medical University Beigang Hospital Coordinator of this site? Confirm its status | Yunlin | Taiwan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.